Twin Peaks Wealth Advisors’s Nurix Therapeutics NRIX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$16	–	1516
2026 Q1	$16	Buy	+1	New	+$17	﹤0.01%	2353
2025 Q3	–	Sell	-1	Closed	-$10	–	1437
2025 Q2	$10	Buy	+1	New	+$11	﹤0.01%	2267

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Twin Peaks Wealth Advisors's NRIX Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 1 share — an estimated $16 sold.

Twin Peaks Wealth Advisors first reported a position in NRIX in Q2 2025 and held it in 2 quarters. The position peaked at $16 in Q1 2026. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Twin Peaks Wealth Advisors reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
Twin Peaks Wealth Advisors sold 1 Nurix Therapeutics share in Q2 2026, an estimated $16.
Twin Peaks Wealth Advisors first reported a position in Nurix Therapeutics in Q2 2025 and held it in 2 quarters.
Twin Peaks Wealth Advisors's Nurix Therapeutics position peaked at $16 in Q1 2026.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.